ResoTher Pharma is excited to announce that the company has won a Phase I SME grant under the European Union Horizon2020 funding scheme. The grant will support the preparations for clinical development of RTP-026, a novel peptide drug for resolution of inflammation....

ResoTher Pharma and Professor Mauro Perretti, William Harvey Research Institute, Barts and the London School of Medicine, is pleased to announce that the partners together have won a Translational Research grant in the amount of £ 489.000 from Barts Charity London....

ResoTher Pharma is pleased to announce that the company has been awarded an Innobooster grant in the amount of DKK 4.900.000 from the Danish Innovation Foundation. The award will fund the continued development of RTP-026, a novel peptide FPR2 agonist.  RTP-026 has...

ResoTher Pharma has been selected as one of the up-and-coming biotech companies to watch and will be featured at the StartUp Spotligt at this years BioEurope Spring convention on March 26th, 2019. We are pleased with the recognition and look forward to a productive...

ResoTher Pharma is pleased to announce that Paul Hargreaves, MSc, MBA will take on the role as Chief Development Officer with responsibility for the company´s clinical activities. Mr. Hargreaves is a pharma veteran and bring with him extensive experience with clinical...

Today ResoTher Pharma was profiled by the prominent Danish biotech publication MedWatch. The article can be viewed by following the link here.

ResoTher Pharma is extremely pleased to announce our nomination as winner of the European-wide 2019 Advance Biotech Awards, issued by German pharma conglomerate Merck AG. ResoTher Pharma was one of many European contestants for the prestigious award and was selected...

ResoTher Pharma management is pleased to announce that Joel Scherer, MD has joined the company´s Scientific Advisory Board. Dr. Scherer brings considerable drug development and cardiology expertise from his former roles as Chief Medical Officer, Managing Director at...

Kirsten Drejer, PhD takes on the role as Chairwoman of the Board of ResoTher Pharma following a unanimous vote at the company´s general assembly. “We are extremely pleased with the collaboration with Kirsten, who has a wealth of experience to contribute to a company...

The management of ResoTher Pharma is pleased to announce that consulting cardiologist and Professor Thomas Engstrøm, MD joins the company´s scientific advisory board as an expert clinical advisor. Dr. Engstrøm is an expert in the diagnosis and treatment of Myocardial...